New serological markers for the differential diagnosis of autoimmune limbic encephalitis;Neue serologische Marker zur Differentialdiagnose der Autoimmun- Enzephalitis

LaboratoriumsMedizin

Volumn 35, Issue 6, 2011, Pages 329-342

  Wandinger, Klaus Peter ^a   Klingbeil, Christine ^a   Gneiss, Claudia ^b   Waters, Patrick ^c   Dalmau, Josep ^d   Saschenbrecker, Sandra ^a   Borowski, Kathrin ^a   Deisenhammer, Florian ^b   Vincent, Angela ^c   Probst, Christian ^a   Stöcker, Winfried ^a  

^a Institute of Experimental Immunology   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMPA receptor; autoimmune encephalitis; BIOCHIP mosaic; CASPR2; differential diagnosis; GABA B receptor; indirect immunofl uorescence; LGI1; neuropil antibodies; NMDA receptor; voltage gated potassium channel (VGKC)

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; GLUTAMATE RECEPTOR ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE ENCEPHALITIS; CANCER SURGERY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GOOD LABORATORY PRACTICE; HUMAN; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; PARANEOPLASTIC NEUROPATHY; SEROLOGY;

EID: 81055144560     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2011.059     Document Type: Article

References (121)

1. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneo-plastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40. (Pubitemid 39005770)
2. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007;13:261-71. (Pubitemid 47396312)
3. Rosenfeld MR, Dalmau J. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin Neurol 2010;30:320-31.
4. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010;257:509-17.
5. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481-94. (Pubitemid 30420947)
6. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000;47:9-17. (Pubitemid 30033645)
7. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre J Y. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999;45:162-7. (Pubitemid 29072361)
8. Rousseau A, Benyahia B, Dalmau J, Connan F, Guillet JG, Delattre J Y, et al. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005;71:231-6. (Pubitemid 40372950)
9. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992;71:59-72.
10. Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409-18. (Pubitemid 36644385)
11. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005;128:1764-77. (Pubitemid 41373648)
12. Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 2007;78:381-5. (Pubitemid 46580546)
13. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36. (Pubitemid 46214241)
14. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.
15. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-34.
16. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67-76.
17. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776-85.
18. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011;69:303-11.
19. Irani S.R, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734-48.
20. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
21. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-8.
22. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655-67.
23. Lebas A, Husson B, Didelot A, Honnorat J, Tardieu M. Expanding spectrum of encephalitis with NMDA receptor antibodies in young children. J Child Neurol 2010;25:742-5.
24. Zandi MS, Irani SR, Follows G, Moody AM, Molyneux P, Vincent A. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology 2009;73:2039-40.
25. Graus F, Boronat A, Xifro X, Boix M, Svigelj V, Garcia A, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010;74:857-9.
26. Bataller L, Galiano R, Garcia-Escrig M, Martinez B, Sevilla T, Blasco R, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010;74:265-7.
27. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011;76:795-800.
28. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892-900.
29. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010;5:S277-80.
30. Yashiro K, Philpot BD. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008;55:1081-94.
31. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007;8:413-26. (Pubitemid 46789232)
32. Qiu S, Hua YL, Yang F, Chen YZ, Luo JH. Subunit assembly of N-methyl-d-aspartate receptors analyzed by fluorescence resonance energy transfer. J Biol Chem 2005;280:24923-30. (Pubitemid 40934584)
33. Palmer CL, Cotton L, Henley JM. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 2005;57:253-77. (Pubitemid 41043886)
34. Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 2006;326:447-55. (Pubitemid 44435820)
35. Genoux D, Montgomery JM. Glutamate receptor plasticity at excitatory synapses in the brain. Clin Exp Pharmacol Physiol 2007;34:1058-63. (Pubitemid 47274556)
36. Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 2007;23:613-43.
37. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 2004;84:835-67. (Pubitemid 38823768)
38. Schwenk J, Metz M, Zolles G, Turecek R, Fritzius T, Bildl W, et al. Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature 2010;465:231-5.
39. Padgett CL, Slesinger PA. GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol 2010;58:123-47.
40. Collingridge GL, Isaac JT, Wang YT. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 2004;5:952-62. (Pubitemid 39593358)
41. Gaiarsa JL, Caillard O, Ben-Ari Y. Long-term plasticity at GABAergic and glycinergic synapses: mechanisms and functional significance. Trends Neurosci 2002;25:564-70. (Pubitemid 35254180)
42. Kalachikov S, Evgrafov O, Ross B, Winawer M, Barker-Cummings C, Martinelli BF, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002;30:335-41.
43. Chernova OB, Somerville RP, Cowell JK. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene 1998;17:2873-81. (Pubitemid 29010057)
44. Besleaga R, Montesinos-Rongen M, Perez-Tur J, Siebert R, Deckert M. Expression of the LGI1 gene product in astrocytic gliomas: downregulation with malignant progression. Virchows Arch 2003;443:561-4. (Pubitemid 37363384)
45. Kunapuli P, Chitta KS, Cowell JK. Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene. Oncogene 2003;22:3985-91. (Pubitemid 36819638)
46. Piepoli T, Jakupoglu C, Gu W, Lualdi E, Suarez-Merino B, Poliani PL, et al. Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neuro Oncol 2006;8:96-108. (Pubitemid 46542654)
47. Kobe B, Deisenhofer J. A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature 1995;374:183-6.
48. Fukata Y, Lovero KL, Iwanaga T, Watanabe A, Yokoi N, Tabuchi K, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci USA 2010;107:3799-804.
49. Schulte U, Thumfart JO, Klocker N, Sailer CA, Bildl W, Biniossek M, et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006;49:697-706. (Pubitemid 43290129)
50. Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA, Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006;313:1792-5. (Pubitemid 44454156)
51. Leonardi E, Andreazza S, Vanin S, Busolin G, Nobile C, Tosatto SC. A computational model of the LGI1 protein suggests a common binding site for ADAM proteins. PLoS One 2011;6:e18142.
52. Staub E, Perez-Tur J, Siebert R, Nobile C, Moschonas NK, Deloukas P, et al. The novel EPTP repeat defines a superfamily of proteins implicated in epileptic disorders. Trends Biochem Sci 2002;27:441-4. (Pubitemid 35246249)
53. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008;455:903-11.
54. Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008;17:458-65.
55. Poliak S, Salomon D, Elhanany H, Sabanay H, Kiernan B, Pevny L, et al. Juxtaparanodal clustering of Shaker-like K + channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 2003;162:1149-60. (Pubitemid 37174196)
56. Poliak S, Gollan L, Martinez R, Custer A, Einheber S, Salzer JL, et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K + channels. Neuron 1999;24:1037-47. (Pubitemid 30017681)
57. Horresh I, Poliak S, Grant S, Bredt D, Rasband MN, Peles E. Multiple molecular interactions determine the clustering of Caspr2 and Kv1 channels in myelinated axons. J Neurosci 2008;28:14213-22.
58. Scherer SS, Arroyo EJ. Recent progress on the molecular organization of myelinated axons. J Peripher Nerv Syst 2002;7:1-12. (Pubitemid 34246033)
59. Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010;32:298-309.
60. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011;77:179-89.
61. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759-72.
62. Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci 2011;23:90-7.
63. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93. (Pubitemid 33063773)
64. Wong-Kisiel LC, Ji T, Renaud DL, Kotagal S, Patterson MC, Dalmau J, et al. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology 2010;74:1550-1.
65. Frechette ES, Zhou L, Galetta SL, Chen L, Dalmau J. Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology 2011;76:S64-S66.
66. Luca N, Daengsuwan T, Dalmau J, Jones K, Deveber G, Kobayashi J, et al. Anti-N-methyl-D-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis Rheum 2011.
67. Schimmel M, Bien CG, Vincent A, Schenk W, Penzien J. Successful treatment of anti-N-methyl-D-aspartate receptor encephalitis presenting with catatonia. Arch Dis Child 2009;94:314-6.
68. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008;70:504-11. (Pubitemid 351653374)
69. Iizuka T, Sakai F. Anti-NMDA receptor encephalitis-clinical manifestations and pathophysiology. Brain Nerve 2008;60:1047-60.
70. Ferioli S, Dalmau J, Kobet CA, Zhai QJ, Broderick JP, Espay AJ. Anti-N-methyl-D-aspartate receptor encephalitis: characteristic behavioral and movement disorder. Arch Neurol 2010;67:250-1.
71. Uchino A, Iizuka T, Urano Y, Arai M, Hara A, Hamada J, et al. Pseudo-Piano playing motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis: response to prompt tumor removal and immunotherapy. Intern Med 2011;50:627-30.
72. Breese EH, Dalmau J, Lennon VA, Apiwattanakul M, Sokol DK. Anti-N-methyl-D-aspartate receptor encephalitis: early treatment is beneficial. Pediatr Neurol 2010;42:213-4.
73. Pruss H, Dalmau J, Harms L, Holtje M, Ahnert-Hilger G, Borowski K, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75:1735-9.
74. Wandinger KP, Saschenbrecker S, Stöcker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011;231:86-91.
75. Vincent A, Bien CG. Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol 2008;7:1074-5.
76. Sansing LH, Tuzun E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007;3:291-6. (Pubitemid 46745476)
77. Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE, Rossi JE, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009;66:458-64.
78. Pruss H, Dalmau J, Arolt V, Wandinger KP. Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture. Nervenarzt 2010;81:396-408.
79. Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 2008;23:1256-61.
80. Tuzun E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009;118:737-43.
81. Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 2008;79:324-6. (Pubitemid 351303394)
82. Kumar MA, Jain A, Dechant VE, Saito T, Rafael T, Aizawa H, et al. Anti-N-methyl-D-aspartate receptor encephalitis during pregnancy. Arch Neurol 2010;67:884-7.
83. Alexopoulos H, Kosmidis ML, Dalmau J, Dalakas MC. Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. J Neurol 2011;258: 1568-70.
84. Iizuka T, Yoshii S, Kan S, Hamada J, Dalmau J, Sakai F, et al. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol 2010;257:1686-91.
85. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011;77:589-93.
86. Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 2010;5:31.
87. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-75.
88. Manahan-Vaughan D, von Haebler D, Winter C, Juckel G, Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 2008;18:125-34. (Pubitemid 351413480)
89. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 2007;21:440-52. (Pubitemid 47077295)
90. Schuler V, Luscher C, Blanchet C, Klix N, Sansig G, Klebs K, et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre-and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 2001;31:47-58. (Pubitemid 32757088)
91. Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M, Calver A, et al. Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. Mol Cell Neurosci 2001;17:1059-70. (Pubitemid 32641874)
92. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety-and antidepressant-like behavior. Neuropsychopharmacology 2004;29:1050-62. (Pubitemid 38670043)
93. Gassmann M, Shaban H, Vigot R, Sansig G, Haller C, Barbieri S, et al. Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. J Neurosci 2004;24:6086-97. (Pubitemid 38891099)
94. Gambardella A, Manna I, Labate A, Chifari R, La Russa A, Serra P, et al. GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 2003;60:560-3. (Pubitemid 36246069)
95. Vincent A, Lang B, Kleopa KA. Autoimmune channelopathies and related neurological disorders. Neuron 2006;52:123-38. (Pubitemid 44466364)
96. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70:1883-90. (Pubitemid 351684641)
97. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K + channels: subunit specificity correlates with clinical manifestations. Brain 2006;129:1570-84. (Pubitemid 43999388)
98. Misawa T, Mizusawa H. Anti-VGKCantibody-associatedlimbic encephalitis/Morvan syndrome. Brain Nerve 2010;62:339-45.
99. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopa-thy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-12. (Pubitemid 38295483)
100. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62:1177-82. (Pubitemid 38456513)
101. Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50:73-8.
102. Suleiman J, Brenner T, Gill D, Brilot F, Antony J, Vincent A, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011;76:1252-5.
103. Kaymakamzade B, Kansu T, Tan E, Dericioglu N. LGI1 related limbic encephalitis and response to immunosuppressive therapy. J Neurol [Epub ahead of print, 2011 May 10]. PMID: 21556879. DOI: 10.1007/s00415-011-6044-7.
104. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 2011;76:1355-7.
105. Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, Saenz A, Poza JJ, Galan J, et al. Mutations in the LGI1/epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet 2002;11:1119-28. (Pubitemid 34521092)
106. Nobile C, Michelucci R, Andreazza S, Pasini E, Tosatto SC, Striano P. LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat 2009;30:530-6.
107. Sirerol-Piquer MS, Ayerdi-Izquierdo A, Morante-Redolat JM, Herranz-Perez V, Favell K, Barker PA, et al. The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the cell surface. Hum Mol Genet 2006;15:3436-45. (Pubitemid 44811596)
108. Silva J, Sharma S, Hughes B, Yu YE, Cowell JK. Homozygous inactivation of the LGI1 gene results in hypomyelination in the peripheral and central nervous systems. J Neurosci Res 2010;88:3328-36.
109. Arimura K, Watanabe O. Immune-mediated neuromyotonia (Isaacs'syndrome)- clinical aspects and pathomechanism. Brain Nerve 2010;62:401-10.
110. Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM, et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006;354:1370-7.
111. Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas BH, et al. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry 2008;13:261-6. (Pubitemid 351272653)
112. Tyler KL. Update on herpes simplex encephalitis. Rev Neurol Dis 2004;1:169-78.
113. Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis 2005;16:17-23. (Pubitemid 40430825)
114. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327-40. (Pubitemid 351380534)
115. Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009;28:1421-9.
116. Dale RC, Irani SR, Brilot F, Pillai S, Webster R, Gill D, et al. N-methyl-D-aspartate receptor antibodies in pediatric dys-kinetic encephalitis lethargica. Ann Neurol 2009;66:704-9.
117. Stöcker W, Teegen B, Meyer W, Müller-Kunert E, Proost S, Schlumberger W, et al. Differenzierte Autoantikörper-Diagnostik mit BIOCHIP-Mosaiken. In: Conrad K, editor. Autoantikörper. Lengerich (Deutschland): Pabst Science Publishers 1998;78-99.
118. Wandinger KP, Probst C, Komorowski L, Saschenbrecker S, Rosemann A, Mothes T, et al. Novel recombinant antigenic targets for the determination of (auto)antibodies in autoimmune dermatoses, neurological disorders and gastrointestinal diseases. In: Conrad K, et al., editors. From pathogenesis to therapy of autoimmune diseases. Autoantigens, autoantibodies, autoimmunity 6. Lengerich (Deutschland): Pabst Science Publishers 2009;179-90.
119. Wandinger KP, Dalmau J, Borowski K, Probst C, Fechner K, Stöcker W. Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalitis. In: Conrad K, et al., editors. From pathogenesis to therapy of autoimmune diseases. Autoantigens, autoantibodies, autoimmunity 6. Lengerich (Deutschland): Pabst Science Publishers 2009;434-5.
120. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010;291:52-6.
121. Wandinger KP, Klingbeil C, Waters P, Dalmau J, Saschenbrecker S, Borowski K, et al. Multiparametric serological testing in autoimmune encephalitis using a recombinant immunofluorescence assay and EUROTIDE technology. In: Conrad K, et al., editors. From prediction to prevention of autoimmune diseases. Autoantigens, autoantibodies, autoimmunity 7. Lengerich (Deutschland): Pabst Science Publishers 2011;706-8.